These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10511836)

  • 21. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population prevalence and control of cardiovascular risk factors: what electronic medical records tell us.
    Catalán-Ramos A; Verdú JM; Grau M; Iglesias-Rodal M; del Val García JL; Consola A; Comin E;
    Aten Primaria; 2014 Jan; 46(1):15-24. PubMed ID: 24325864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive examination of health conditions associated with obesity in older adults.
    Patterson RE; Frank LL; Kristal AR; White E
    Am J Prev Med; 2004 Dec; 27(5):385-90. PubMed ID: 15556738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimated economic costs of obesity to U.S. business.
    Thompson D; Edelsberg J; Kinsey KL; Oster G
    Am J Health Promot; 1998; 13(2):120-7. PubMed ID: 10346659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The predicted effects of chronic obesity in middle age on medicare costs and mortality.
    Cai L; Lubitz J; Flegal KM; Pamuk ER
    Med Care; 2010 Jun; 48(6):510-7. PubMed ID: 20473195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging strategies for weight management.
    Hansen BC
    Postgrad Med; 2001 Jun; 109(6 Suppl):3-9. PubMed ID: 19667562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review and economic evaluation of exercise referral schemes in primary care: a short report.
    Campbell F; Holmes M; Everson-Hock E; Davis S; Buckley Woods H; Anokye N; Tappenden P; Kaltenthaler E
    Health Technol Assess; 2015 Jul; 19(60):1-110. PubMed ID: 26222987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
    Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
    J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.
    Zomer E; Leach R; Trimmer C; Lobstein T; Morris S; James WP; Finer N
    Diabetes Obes Metab; 2017 Jan; 19(1):118-124. PubMed ID: 27649286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moderately overweight and obese patients in general practice: a population based survey.
    van Dijk L; Otters HB; Schuit AJ
    BMC Fam Pract; 2006 Jul; 7():43. PubMed ID: 16827937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.
    Maetzel A; Ruof J; Covington M; Wolf A
    Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits of sustained moderate weight loss in obesity.
    Pasanisi F; Contaldo F; de Simone G; Mancini M
    Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):401-6. PubMed ID: 12055705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.
    Murray CJ; Lauer JA; Hutubessy RC; Niessen L; Tomijima N; Rodgers A; Lawes CM; Evans DB
    Lancet; 2003 Mar; 361(9359):717-25. PubMed ID: 12620735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?
    Grover SA; Coupal L; Kaouache M; Lowensteyn I
    Can J Cardiol; 2007 May; 23(6):467-73. PubMed ID: 17487292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beneficial health effects of modest weight loss.
    Goldstein DJ
    Int J Obes Relat Metab Disord; 1992 Jun; 16(6):397-415. PubMed ID: 1322866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and economic characteristics associated with type 2 diabetes.
    Sicras-Mainar A; Navarro-Artieda R; Ibáñez-Nolla J
    Rev Clin Esp (Barc); 2014 Apr; 214(3):121-30. PubMed ID: 24359793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
    Milne RJ; Vander Hoorn S; Jackson RT
    Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium.
    Borisenko O; Lukyanov V; Debergh I; Dillemans B
    J Med Econ; 2018 Apr; 21(4):365-373. PubMed ID: 29271279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol.
    Stason WB
    Am Heart J; 1990 Mar; 119(3 Pt 2):718-24; discussion 724. PubMed ID: 2106765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.